查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003550

全球生物保存市場：按產品、應用、細胞供應和地區分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Biopreservation Market: By Product, Application, Cell Providers Volume, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 290 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球生物保存市場目前正經歷著一場根本性的模式轉移，反映了生命科學和先進治療方法的快速發展及其日益成長的重要性。預計到2025年，該市場規模將達到45.2億美元，並有望迎來爆發性成長，預計到2035年將飆升至444.5億美元。這一顯著成長意味著在2026年至2035年的預測期內，複合年成長率將達到25.68%，凸顯了生物保存產業蓬勃發展的快速勢頭。

市場價值的飆升主要得益於再生醫學、幹細胞研究以及細胞和基因治療（CGT）商業化領域的重大突破和積極發展。這些前沿領域正在革新醫學，為治療以往被認為無法治癒的複雜疾病和病症提供了新的方法。隨著再生醫學和CGT的不斷成熟，對先進可靠的生物保存解決方案的需求也日益成長。

顯著的市場趨勢

生物保存市場正經歷主要企業之間的適度整合，一級企業如賽默飛世爾科技（Thermo Fisher Scientific）、默克集團（Merck KGaA）和安萬特（Avanter，現為VWR）在硬體和通用耗材領域佔據了顯著的市場佔有率。這些行業領導者透過提供涵蓋所有生物保存需求的全面整合解決方案，確立了自身的市場主導地位。他們的策略方針強調提供「端到端」服務，使客戶能夠以單一整合包的形式購買從冷凍庫、儲存管瓶到特種培養基和高級追蹤軟體等所有產品。

近年來，這些市場領導加大了對創新的投入，尤其是在「智慧」整合技術的研發方面。這一趨勢反映了市場對智慧生物保存系統日益成長的需求，這些系統不僅要具備可靠性，還要能夠實現無縫通訊和自動化管理。例如，一些新型冷凍培養基配方應運而生，這些配方專為支援自動化處理而設計。這些培養基的黏度通常較低，從而能夠更順暢地進行機器人操作，並降低自動化工作流程中樣品受損的風險。

同時，冷凍庫技術的進步也解決了樣品安全和災害預防的關鍵問題。製造商現在提供的冷凍庫配備了整合式備用冷卻系統，例如液態氮（LN2）注入裝置，即使在斷電或機械故障的情況下也能維持超低溫。這些備用系統提供了必要的安全措施，防止溫度波動對珍貴且往往不可取代的生物樣本造成損害。

主要成長促進因素

生物保存市場成長的主要驅動力是持續推進的再生醫學革命。在細胞療法和基因療法突破性進展的推動下，這場變革性運動正在重塑醫藥和醫療保健格局。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構正在加速核准創新治療方法，包括CAR-T（嵌合體抗原受體T細胞）療法。 CAR-T療法利用患者自身的免疫細胞標靶並摧毀癌細胞。

新機會的趨勢

生物保存市場真正的「藍海」機會在於常溫保存技術的開發與應用。這些創新方法能夠在常溫下實現乾燥和化學穩定，並有望徹底革新生物樣本的保存方式，擺脫對傳統低溫保存方法的依賴。目前，生物保存產業嚴重依賴液態氮（LN2）和其他低溫工藝，這些工藝需要專用設備、持續的溫度監控以及巨大的能源消耗。常溫保存技術可望從根本上改變這種低溫運輸模式，提供更便利、更經濟、更永續的替代方案。

最佳化障礙

儘管生物保存市場的成長前景普遍樂觀，但該產業仍面臨許多挑戰，這些挑戰可能會阻礙其廣泛應用和發展。其中一個最突出的障礙是自動化技術的高成本，這對小規模實驗室和學術機構構成了重大阻礙。雖然自動化具有許多優勢，包括提高效率、準確性和可重複性，但實施和運行這些先進系統所需的初始投資對於許多預算有限的機構而言仍然難以負擔。

目錄

第1章執行摘要：全球生物保存市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 初步調查受訪者組成：依地區分類
  • 本研究的先決條件
  • 市場規模估算
  • 數據檢驗

第3章：全球生物保存市場概覽

  • 產業價值鏈分析
    • 原料供應商（培養基、試劑、冷凍保護劑）
    • 生物保存設備製造商 [SP1.1]
    • 解決方案和文化媒介提供者
    • 生物樣本庫和儲存設施 [SP2.1]
    • 研究機構和合約研究組織
    • 製藥和生物技術公司
    • 最終使用者（醫院、診斷檢查室）
  • 產業展望
    • 對再生醫學的需求日益成長
    • 擴大生物銀行活動[SP3.1]
    • 器官移植手術增加 [SP4.1]
    • 細胞和基因治療研究的擴展 [SP5.1]
    • 增加對生物技術領域的投資[SP6.1]
    • 對個人化醫療的需求日益成長 [SP7.1]
    • 冷凍保存技術的進展 [SP8.1]
    • 政府和私部門增加資金籌措
  • PESTLE分析
  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態和趨勢
    • 成長促進因素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場成長及前景
    • 2020-2035年市場收益估算與預測
    • 按原物料分析價格趨勢

第4章 競爭格局概述

  • 市場集中度
  • 企業市場占有率分析（以金額為準，%），2025 年
  • 競爭對手分析與基準測試
  • Start-Ups生態系分析
  • 併購和資金籌措趨勢

第5章：全球生物防腐市場分析

  • 關鍵見解
  • 市場規模及預測（2020-2035）
    • 依產品
    • 透過使用
    • 按細胞供應量
    • 按地區

第6章：北美生物保存市場分析

第7章：歐洲生物保存市場分析

第8章：亞太地區生物保存市場分析

第9章：中東和非洲生物保存市場分析

第10章：南美洲生物保存市場分析

第11章：公司簡介

  • Azenta US, Inc.
  • BioLife Solutions
  • LabVantage Solutions, Inc.
  • Biomatrica, Inc.
  • MVE Biological Solutions
  • Thermo Fisher Scientific, Inc.
  • Panasonic
  • X-Therma Inc.
  • PrincetonCryo
  • Stirling Ultracold
  • Taylor-Wharton
  • 其他有潛力的企業

第12章附錄

簡介目錄
Product Code: AA01261689

The global biopreservation market is currently experiencing a profound and transformative paradigm shift, reflecting the rapid evolution and growing importance of life sciences and advanced therapies. Valued at USD 4.52 billion in 2025, the market is poised for exponential growth, with projections estimating its valuation to soar to an impressive USD 44.45 billion by 2035. This remarkable expansion corresponds to a compound annual growth rate (CAGR) of 25.68% over the forecast period from 2026 to 2035, underscoring the dynamic pace at which the biopreservation sector is advancing.

This surge in market value is primarily fueled by significant breakthroughs and heightened activity in regenerative medicine, stem cell research, and the commercialization of cell and gene therapies (CGT). These cutting-edge fields are revolutionizing medical science by offering novel approaches to treat complex diseases and conditions that were previously considered untreatable. As regenerative medicine and CGT continue to mature, the need for sophisticated and reliable biopreservation solutions becomes increasingly critical.

Noteworthy Market Developments

The biopreservation market exhibits a moderate level of consolidation among its leading companies, with Tier 1 players such as Thermo Fisher Scientific, Merck KGaA, and Avantor (VWR) commanding a significant share of the hardware and general consumables segments. These industry giants have established themselves as dominant forces by offering comprehensive, integrated solutions that encompass the full spectrum of biopreservation needs. Their strategic approach focuses on providing "end-to-end" services, where customers can purchase everything from freezers and storage vials to specialized media and advanced tracking software as a cohesive, bundled package.

In recent years, these market leaders have intensified their focus on innovation, particularly through the development of "smart" integration technologies. This trend reflects a growing demand for biopreservation systems that are not only reliable but also intelligent, capable of seamless communication and automated management. For instance, new cryo-media formulations are being introduced that are specifically engineered to support automated handling processes. These media tend to have lower viscosity, which facilitates smoother robotic manipulation and reduces the risk of sample damage during automated workflows.

Simultaneously, advancements in freezer technology are addressing critical concerns related to sample safety and disaster prevention. Manufacturers are launching freezers equipped with integrated backup cooling systems, such as liquid nitrogen (LN2) injection mechanisms, designed to maintain ultra-low temperatures even during power outages or mechanical failures. These backup systems provide an essential safeguard against temperature excursions that could otherwise compromise valuable and often irreplaceable biological samples.

Core Growth Drivers

The primary engine propelling growth in the biopreservation market is the ongoing Regenerative Medicine Revolution. This transformative movement, driven by groundbreaking advancements in cell and gene therapies, is reshaping the pharmaceutical and healthcare landscapes. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accelerated the approval of innovative therapies, including CAR-T (chimeric antigen receptor T-cell) treatments, which harness patients' own immune cells to target and destroy cancer cells.

Emerging Opportunity Trends

The true "Blue Ocean" opportunity within the biopreservation market lies in the development and adoption of room-temperature storage technologies. These innovative approaches have the potential to revolutionize the way biological samples are preserved by enabling desiccation or chemical stabilization at ambient temperatures, thereby eliminating the traditional dependence on ultra-cold storage methods. Currently, the biopreservation industry relies heavily on liquid nitrogen (LN2) and other cryogenic processes, which require specialized equipment, continuous temperature monitoring, and significant energy consumption. Room-temperature storage technologies promise to disrupt this cold chain paradigm entirely, offering a more accessible, cost-effective, and sustainable alternative.

Barriers to Optimization

Despite the prevailing optimism surrounding the growth of the biopreservation market, the industry continues to face significant challenges that could hinder its broader adoption and development. One of the most notable obstacles is the high cost associated with automation technologies, which poses a considerable barrier for smaller laboratories and academic institutions. While automation offers numerous advantages, such as improved efficiency, accuracy, and reproducibility, the initial capital expenditure required to acquire and implement these advanced systems remains prohibitively expensive for many organizations operating with limited budgets.

Detailed Market Segmentation

By product category, the media segment is poised to experience extraordinary growth, with a projected compound annual growth rate (CAGR) of 32% over the forecast period from 2026 to 2035. This remarkable expansion signals one of the most significant value shifts within the bio-preservation and related life sciences industries. It reflects a fundamental change in how companies and laboratories allocate resources, moving away from traditional, capital-intensive investments in hardware toward a greater emphasis on consumable products that require frequent replenishment.

  • In terms of sample volume, the induced pluripotent stem cell (iPSC) segment is anticipated to experience robust growth throughout the forecast period, reflecting its increasing importance and adoption in biomedical research and therapeutic applications. iPSCs have garnered significant attention due to their unique capabilities and advantages over traditional stem cell sources, positioning them as a critical component in the expanding field of regenerative medicine and personalized therapies.

By application, the biobanking category has emerged as the leader in the global bio-preservation market, reflecting its critical role in the evolving landscape of biomedical research and therapy development. As of 2025, the dialogue surrounding bio-preservation has transformed significantly, moving beyond the traditional notion of mere "storage" of biological materials to a more strategic focus on supply chain resilience. This shift acknowledges the importance of bio-preservation not just as a passive repository but as an active component in ensuring the availability, integrity, and timely distribution of critical biological samples and materials across complex therapeutic networks.

Segment Breakdown

By Product

  • Equipment
  • Refrigerators
  • Freezers
  • Consumables
  • Straws
  • Vials
  • Microtiter Plates
  • Bags
  • Liquid Nitrogen
  • Media
  • Home-brew
  • Pre-formulated
  • Laboratory Information Management System (LIMS)

By Application

  • Regenerative Medicine
  • Gene Therapy
  • Cell Therapy
  • Others
  • Bio-banking
  • Human Sperms
  • Human Eggs
  • Veterinary IVF
  • Drug Discovery

By Cell Providers Volume

  • CD19+
  • CD34+
  • iPSC
  • MSC
  • Tumor Cells
  • hESC
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America stands as the mature innovator within the global pharmaceutical and biotechnology landscape, contributing over 47% of the total market revenue. This region's dominant position is the result of several interrelated factors, including substantial investment in research and development (R&D) and the concentration of major pharmaceutical conglomerates headquartered within its borders. These elements combine to create a robust ecosystem that fosters innovation, accelerates the development of cutting-edge therapies, and sustains the region's leadership in the global market.
  • The United States, in particular, serves as the global epicenter for cell therapy development. This leadership role is supported by the presence of critical regulatory and funding institutions such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). Together, these organizations establish a rigorous but well-resourced environment that promotes scientific advancement while ensuring patient safety and regulatory compliance. The FDA's stringent approval processes, combined with the NIH's substantial research funding, create a balanced framework that encourages innovation while maintaining high standards.

Leading Market Participants

  • Azenta US, Inc.
  • BioLife Solutions
  • LabVantage Solutions, Inc.
  • Biomatrica, Inc.
  • MVE Biological Solutions
  • Thermo Fisher Scientific, Inc.
  • Panasonic
  • X-Therma Inc.
  • PrincetonCryo
  • Stirling Ultracold
  • Taylor-Wharton
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Biopreservation Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Biopreservation Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers (Media, Reagents, Cryoprotectants)
    • 3.1.2. Biopreservation Equipment Manufacturers[SP1.1]
    • 3.1.3. Solution & Media Providers
    • 3.1.4. Biobanks & Storage Facilities[SP2.1]
    • 3.1.5. Research Institutes & CROs
    • 3.1.6. Pharmaceutical & Biotechnology Companies
    • 3.1.7. End Users (Hospitals, Diagnostic Labs)
  • 3.2. Industry Outlook
    • 3.2.1. Rising Demand for Regenerative Medicine
    • 3.2.2. Growth in Biobanking Activities[SP3.1]
    • 3.2.3. Increasing Organ Transplantation Procedures[SP4.1]
    • 3.2.4. Expansion of Cell & Gene Therapy Research[SP5.1]
    • 3.2.5. Rising Investments in Biotechnology Sector[SP6.1]
    • 3.2.6. Growing Demand for Personalized Medicine[SP7.1]
    • 3.2.7. Technological Advancements in Cryopreservatio[SP8.1]n
    • 3.2.8. Increasing Government & Private Funding
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Dynamics and Trends
    • 3.5.1. Growth Drivers
      • 3.5.1.1. Rising Demand for Regenerative Medicine
    • 3.5.2. Restraints
    • 3.5.3. Opportunity
    • 3.5.4. Key Trend
  • 3.6. Market Growth and Outlook
    • 3.6.1. Market Revenue & Volume Estimates and Forecast (US$ Mn), 2020 - 2035
    • 3.6.2. Price Trend Analysis, by Feedstock

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking
  • 4.4. Startup Ecosystem Analysis
  • 4.5. M&A and Funding Landscape

Chapter 5. Global Biopreservation Market Analysis

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product
      • 5.2.1.1. Equipment
        • 5.2.1.1.1. Refrigerators
        • 5.2.1.1.2. Freezers
        • 5.2.1.1.3. Consumables
          • 5.2.1.1.3.1. Straws
          • 5.2.1.1.3.2. Vials
          • 5.2.1.1.3.3. Microtiter Plates
        • 5.2.1.1.4. Bags
        • 5.2.1.1.5. Liquid Nitrogen
      • 5.2.1.2. Media
        • 5.2.1.2.1. Home-brew
        • 5.2.1.2.2. Pre-formulated
      • 5.2.1.3. Laboratory Information Management System (LIMS)
    • 5.2.2. By Application
      • 5.2.2.1. Regenerative Medicine
        • 5.2.2.1.1. Gene Therapy
        • 5.2.2.1.2. Cell Therapy
        • 5.2.2.1.3. Others
      • 5.2.2.2. Bio-banking
        • 5.2.2.2.1. Human Sperms
        • 5.2.2.2.2. Human Eggs
        • 5.2.2.2.3. Veterinary IVF
      • 5.2.2.3. Drug Discovery
    • 5.2.3. By Cell Providers Volume
      • 5.2.3.1. CD19+
      • 5.2.3.2. CD34+
      • 5.2.3.3. IPSC
      • 5.2.3.4. MSC
      • 5.2.3.5. Tumor Cells
      • 5.2.3.6. HESC
      • 5.2.3.7. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
        • 5.2.4.1.1. The U.S.
        • 5.2.4.1.2. Canada
        • 5.2.4.1.3. Mexico
      • 5.2.4.2. Europe
        • 5.2.4.2.1. Western Europe
          • 5.2.4.2.1.1. The UK
          • 5.2.4.2.1.2. Germany
          • 5.2.4.2.1.3. France
          • 5.2.4.2.1.4. Italy
          • 5.2.4.2.1.5. Spain
          • 5.2.4.2.1.6. Rest of Western Europe
        • 5.2.4.2.2. Eastern Europe
          • 5.2.4.2.2.1. Poland
          • 5.2.4.2.2.2. Russia
          • 5.2.4.2.2.3. Rest of Eastern Europe
      • 5.2.4.3. Asia Pacific
        • 5.2.4.3.1. China
        • 5.2.4.3.2. India
        • 5.2.4.3.3. Japan
        • 5.2.4.3.4. South Korea
        • 5.2.4.3.5. Australia & New Zealand
        • 5.2.4.3.6. ASEAN
          • 5.2.4.3.6.1. Indonesia
          • 5.2.4.3.6.2. Malaysia
          • 5.2.4.3.6.3. Thailand
          • 5.2.4.3.6.4. Singapore
          • 5.2.4.3.6.5. Rest of ASEAN
        • 5.2.4.3.7. Rest of Asia Pacific
      • 5.2.4.4. Middle East & Africa
        • 5.2.4.4.1. UAE
        • 5.2.4.4.2. Saudi Arabia
        • 5.2.4.4.3. South Africa
        • 5.2.4.4.4. Rest of MEA
      • 5.2.4.5. South America
        • 5.2.4.5.1. Argentina
        • 5.2.4.5.2. Brazil
        • 5.2.4.5.3. Rest of South America

Chapter 6. North America Biopreservation Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Cell Providers Volume
    • 6.2.4. By Country

Chapter 7. Europe Biopreservation Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Cell Providers Volume
    • 7.2.4. By Country

Chapter 8. Asia Pacific Biopreservation Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Cell Providers Volume
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Biopreservation Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Cell Providers Volume
    • 9.2.4. By Country

Chapter 10. South America Biopreservation Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Cell Providers Volume
    • 10.2.4. By Country

Chapter 11. Company Profile ([SP9.1]Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Azenta US, Inc.
  • 11.2. BioLife Solutions
  • 11.3. LabVantage Solutions, Inc.
  • 11.4. Biomatrica, Inc.
  • 11.5. MVE Biological Solutions
  • 11.6. Thermo Fisher Scientific, Inc.
  • 11.7. Panasonic
  • 11.8. X-Therma Inc.
  • 11.9. PrincetonCryo
  • 11.10. Stirling Ultracold
  • 11.11. Taylor-Wharton
  • 11.12. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Macro-Economic Outlook/Indicators